| Drug Name |
Entacapone |
| Drug ID |
BADD_D00773 |
| Description |
Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor. |
| Indications and Usage |
Used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose "wearing-off". |
| Marketing Status |
approved; investigational |
| ATC Code |
N04BX02 |
| DrugBank ID |
DB00494
|
| KEGG ID |
D00781
|
| MeSH ID |
C071192
|
| PubChem ID |
5281081
|
| TTD Drug ID |
D0J1VY
|
| NDC Product Code |
47335-007; 62332-478; 64679-711; 52483-0014; 33342-260; 50268-295; 60687-188; 71610-247; 0781-5578; 64679-781; 48087-0080; 68022-7015; 65862-654; 0615-8298; 68554-0068; 65085-0050; 65862-611; 27241-049; 58032-2003; 65372-1149; 68022-7043; 46708-478; 0527-1830; 17511-109; 46438-0005; 49587-105; 48087-0109; 52427-800 |
| UNII |
4975G9NM6T
|
| Synonyms |
entacapone | 2-cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide | Comtan | Comtess | OR 611 | OR-611 |
